Sage Journals: Discover world-class research

Abstract

Objective: Evidence regarding comedication among individuals with ADHD is lacking, especially in adults. This study investigated comedication and polypharmacy with ADHD medications in adults. Method: We identified adults dispensed with ADHD medications during 2013 in Sweden and matched them to controls. Logistic regression was used to calculate odds ratios (ORs) of receiving other medications. Results: Individuals receiving ADHD medications had higher risk of receiving any major classes of somatic medications (ORs ranged from 4.1, 95% confidence interval [CI] = [4.0, 4.3], to 7.4, 95% CI = [6.5, 8.5] across age groups). They were more likely to receive respiratory system, alimentary tract and metabolic system, and cardiovascular system medications. In addition, they had higher risk of receiving any other psychotropic medications. The proportion of polypharmacy with five or more medication classes increased from 10.1% to 60.4% from 18 to 64 years. Conclusion: Comedication was more common in adults receiving ADHD medications. Potential benefits and harms of comedication and polypharmacy require further research. (J. of Att. Dis. XXXX; XX[X] XX-XX)

Keywords

ADHD medications comedication somatic medications polypharmacy

Introduction

ADHD is a common neurodevelopmental disorder, affecting 5% to 8% of children (Polanczyk et al., 2014; Thomas et al., 2015) and 3% of adults worldwide (Simon et al., 2009). Although ADHD usually has its onset in childhood, follow-up studies have shown that the disorder often persists into adulthood (Faraone et al., 2006) and that it is associated with long-term health problems (Ingram et al., 1999; Nigg, 2013). The prevalence of ADHD medication use among adults has increased substantially over the last decade. For example, the prevalence of any ADHD medication use in 2010 was 1.42% in North America and 0.47% in northern Europe, with annual average increase of 10% and 19% from 2000, respectively (Raman et al., 2018).

It is well established that patients with ADHD have high rates of psychiatric comorbidities (Comer et al., 2010; Karlstad et al., 2016; Larson et al., 2011). Emerging evidence has shown that young individuals with ADHD often have somatic comorbidities, such as metabolic syndrome (Fluegge & Fluegge, 2018), disorders of chronic inflammation (e.g., asthma and allergic rhinitis; Cortese et al., 2018; Schmitt et al., 2016), and cardiovascular disorders (Arruda et al., 2010), but much less is known about comorbidities among middle-aged and older adults with ADHD. As both adult ADHD and the aforementioned comorbid disorders feature a chronic, long-lasting course, it may result in long treatment periods with simultaneous use of multiple medications. Although use of multiple medications has been associated with increased risks of adverse drug events, including nonadherence, cumulative toxicity, and drug–drug interactions (Sarkar, 2017; Sirois et al., 2016), very little is known about comedication and polypharmacy patterns associated with ADHD medication. Moreover, there is limited information on how to address comedication in treatment guidelines for ADHD (National Institute for Health and Care Excellence [NICE], 2018; Swedish National Board of Health and Welfare [Swedish: Socialstyrelsen], 2014; Wolraich et al., 2019).

By taking advantage of Swedish national registers, this nationwide study investigated the comedication (including both somatic [nonpsychotropic] and psychotropic medications) and polypharmacy patterns with ADHD medications among adults.

Method

National Registers and Study Population

Data were available through linkage of the Prescribed Drug Register (PDR), the Total Population Register (TPR), and the National Patient Register (NPR) in Sweden based on the unique personal identification numbers (Ludvigsson et al., 2009). The PDR covers information on all prescribed medications dispensed at pharmacies in Sweden since July 2005, which includes drug identity (defined using Anatomical Therapeutic Chemical [ATC] codes), dose, dates of dispensed prescriptions, and the prescriber’s profession and practice (Wettermark et al., 2007). The proportion of invalid dispensation entries in the PDR is expected to be below 2% (Furu et al., 2010). The TPR was established by Statistics Sweden and covers demographic information since 1968. This includes information on births, deaths, place of residence, civil status, migration, relations, and citizenship of all Swedish residents, and has virtually complete coverage of births and deaths (Ludvigsson et al., 2016). The NPR contains data on inpatient diagnoses since 1973 (Ludvigsson et al., 2011) and outpatient diagnoses since 2001 based on the International Classification of Diseases (ICD). Information from the PDR was used to identify dispensations of ADHD medications and other medications. The TPR was used to obtain information on date of birth and sex. Information from the NPR was used to identify individuals with ADHD diagnosis.

The target population included all individuals aged 18 to 64 years who were residing in Sweden during 2013. Among whom, all individuals who had at least one dispensed prescription of ADHD medication during the study period were identified. A randomly selected 1:1 control group of individuals without any ADHD medication prescriptions in 2013 was created by matching on year of birth and sex as individuals with ADHD medication prescriptions.

Measures

Information on ADHD medication was defined from the PDR. Four stimulants (methylphenidate [ATC code: N06BA04], amfetamine [N06BA01], dexamfetamine [N06BA02], and lisdexamfetamine [N06BA12]) and two nonstimulants (atomoxetine [N06BA09] and guanfacine [C02AC02]) were included in this study. For sensitivity analysis, information on ADHD diagnosis was obtained from the NPR, where diagnostic codes in ICD-9 (1987–1996, codes 314) and ICD-10 (1997–2013, codes F90) were used.

To describe prescription patterns, we retrieved information on the source of prescription (primary care, nonpsychiatric specialist care, and psychiatric care) and the duration of prescriptions from the PDR. In accordance with previous studies (Lagerberg et al., 2019; Lichtenstein et al., 2012), an individual was considered to be receiving treatment during the interval between two dispensed ADHD medication prescriptions if these occurred less than 6 months apart. The longest treatment period for each individual during a year was considered.

Comedication with ADHD medication was defined as dispensed prescriptions of any other medication within 6 months before and after an ADHD medication prescription (Lagerberg et al., 2019). Medications were ascertained based on first-level ATC codes, which include alimentary tract and metabolism (gastrointestinal tract and metabolic system (A); cardiovascular system (C); dermatologicals (D); genitourinary system and reproductive hormones (G); systemic hormonal preparations (H); anti-infectives (antibiotics, antifungals, antiparasitic agents, and antivirals) for systemic use (J); antineoplastic and immunomodulating agents (L); musculoskeletal system (M); nervous system (N); antiparasitic products, insecticides, and repellents (P); respiratory system (R); and sensory organs (S). Detailed information on ATC codes of medications included in our study is shown in Supplemental Table S1.

In addition to these main drug classes, we investigated dispensation of other psychotropic medications among individuals receiving ADHD medications, including antipsychotics (N05A); anxiolytics, hypnotics, and sedatives (N05B or N05C); antidepressants (N06A); antiepileptic drugs (N03A); drugs used in addictive disorders (substance use disorders, N07B); and opioid pain medications (N02A; Supplemental Table S1).

Statistical Analyses

Patterns of ADHD medication prescriptions in relation to ADHD medication type, source of prescription, and duration of prescription in 2013 are reported as number and percentage. We examined the proportion of individuals receiving any somatic and psychotropic medications among individuals receiving ADHD medications and controls, as well as for each major ATC class. Logistic regression models were performed to estimate odds ratios (ORs) for receiving each drug class in those receiving ADHD medications versus controls, with adjustment for sex and age as a categorical variable (Pearce, 2016). ORs and 95% confidence intervals (CIs) were presented by age group (young adults [18–29 years], middle-aged adults [30–49 years], older adults [50–64 years]). Polypharmacy pattern (measured as the number of major classes of medications in addition to ADHD medications) was presented for individuals receiving ADHD medications and controls. All statistical analyses were performed using SAS version 9.4 (SAS Institute) and we used a threshold of p < .05 for statistical significance. Figures were created in R software version 3.5.0.

Results

We identified 41,840 adults aged 18 to 64 years residing in Sweden who dispensed at least one prescription of ADHD medications in 2013, including 20,629 young adults (men 11,220 [54.39%]), 16,889 middle-aged adults (men 8,931 [52.88%]), and 4,322 older adults (men 2,339 [54.12%]). Table 1 shows the prescription patterns of ADHD medication in young, middle-aged, and older adults in 2013. Overall, methylphenidate was the most commonly dispensed medication (82%–90% in all age groups), whereas the proportion of lisdexamfetamine and guanfacine accounted for less than 1%. Psychiatric care was the most prevalent source of prescription (ranged from 87.90%–92.84%), followed by other specialist care (from 6.31%–10.50%) and primary care (from 0.86%–1.36%). The majority of individuals who dispensed ADHD prescriptions experienced treatment periods longer than 1 year for all age groups. The prescription patterns were similar between men and women (Supplemental Table S2).

Table 1.

Patterns of ADHD Medication Prescriptions Among Adults in 2013, Stratified by Age Group.

Characteristics	Young adults^a (N = 20,629)	Middle-aged adults (N = 16,889)	Older adults (N = 4,322)
Type (%)
Methylphenidate	18,381 (89.10%)	14,672 (86.87%)	3,584 (82.92%)
Atomoxetine	3,236 (15.69%)	2,232 (13.22%)	547 (12.66%)
Lisdexamfetamine	137 (0.66%)	177 (1.05%)	33 (0.76%)
Amfetamine	141 (0.68%)	337 (2.00%)	218 (5.04%)
Dexamfetamine	442 (2.14%)	945 (5.60%)	254 (5.88%)
Guanfacine	7 (0.03%)	1 (0.01%)	1 (0.02%)
Source (%)
Primary care	280 (1.36%)	145 (0.86%)	69 (1.60%)
Specialist care^b	1,393 (6.75%)	1,065 (6.31%)	454 (10.50%)
Psychiatric care	18,956 (91.89%)	15,679 (92.84%)	3,799 (87.90%)
Duration of medication (%)
Single prescription^c	1,438 (6.97%)	686 (4.06%)	197 (4.56%)
Short term (≤6 months)	2,189 (10.61%)	1,164 (6.89%)	273 (6.32%)
Medium term (6–12 months)	2,434 (11.80%)	1,424 (8.43%)	310 (7.17%)
Long term (>12 months)	14,568 (70.62%)	13,615 (80.61%)	3,542 (81.95%)

Young adults refer to patients aged 18–29 years; middle-aged adults refer to patients aged 30–49 years; older adults referred to patients aged 50–64 years.

Specialist care excluding psychiatry.

Single prescription here entails single dispensed prescriptions of any ADHD medication. Switching between different types of ADHD medications is not captured by this number.

Comedication With Somatic Medications in Individuals Receiving ADHD Medications

Overall, the percentage of individuals coprescribed with any somatic medications increased with age, from 76.7% in young adults to 93.4% in older adults (Table 2). The proportion of dispensation with any somatic medication was higher among individuals receiving ADHD medications than controls, with ORs ranging from 4.1 (95% CI = [4.0, 4.3]) in young adults to 7.4 (95% CI = [6.5, 8.5]) in older adults.

Table 2.

Dispensations of Any Somatic and Other Psychotropic Medications Among Individuals Receiving ADHD Medications.

Comedication	Age group	ADHD drug users (N = 41,840)	Control group (N = 41,840)	Odds ratio [95% CI]
Somatic medications	Young adults (18–29 years)	15,818 (76.7%)	10,134 (49.1%)	4.1 [4.0, 4.3]
	Middle-aged adults (30–49 years)	14,631 (86.6%)	8,951 (53.0%)	6.2 [5.9, 6.6]
	Older adults (50–64 years)	4,037 (93.4%)	2,865 (66.3%)	7.4 [6.5, 8.5]
Psychotropic medications	Young adults (18–29 years)	13,812 (67.0%)	2,673 (13.0%)	15.5 [14.7, 16.3]
	Middle-aged adults (30–49 years)	14,458 (85.6%)	3,846 (22.8%)	21.7 [20.5, 23.0]
	Older adults (50–64 years)	3,859 (89.3%)	1,394 (32.3%)	18.6 [16.5, 20.9]

Note. CI = confidence interval.

For each specific class of somatic medications, individuals receiving ADHD medications had higher odds of receiving them compared with controls for all age groups (Figure 1). Among all major classes of medications, respiratory system medications have the highest odds of being dispensed when comparing individuals with ADHD medication prescriptions with controls. The ORs ranged from 4.8 (95% CI = [4.5, 5.0]) among young adults to 5.6 (95% CI = [5.3, 5.8]) among middle-aged adults. Supplemental Table S3 lists the 10 most commonly dispensed medications in the respiratory system medication class among individuals receiving ADHD medications.

Figure 1.

Dispensation of somatic medications (according to ATC classes) among individuals receiving ADHD medications, by age group.

Alimentary tract and metabolic system medications are associated with the second highest ORs of being dispensed, in individuals with ADHD medication prescriptions versus controls. The ORs ranged from 4.0 (95% CI = [3.6, 4.4]) among older adults to 4.7 (95% CI = [4.4, 5.0]) among middle-aged adults. Supplemental Table S4 lists the 10 most commonly dispensed medications in this class among individuals dispensed with ADHD medications.

Cardiovascular system medications have the third highest ORs of being dispensed when comparing individuals with ADHD medication prescriptions with controls. The OR of receiving cardiovascular system medications was the highest among young adults (OR = 4.5, 95% CI = [4.1, 5.0]). The association attenuated with age, but remained significant among older adults (OR = 2.2, 95% CI = [2.0, 2.4]). Supplemental Table S5 lists the 10 most commonly dispensed medications in this class among individuals dispensed with ADHD medications.

Sensitivity analyses showed that the comedication patterns among individuals with both ADHD diagnosis and ADHD medication versus controls are similar to the main analysis (Supplemental Figure S1). Men and women receiving ADHD medications showed similar comedication patterns except that men had a lower proportion but higher OR of receiving genitourinary and reproductive hormone medications (Supplemental Figure S2).

Comedication With Other Psychotropic Medications in Individuals Receiving ADHD Medications

The odds of comedication with any other psychotropic medications was substantially higher among individuals dispensed with ADHD medications than controls (Table 2), with highest ORs in middle-aged adults (OR = 21.7, 95% CI = [20.5, 23.0]), followed by older adults (OR = 18.6, 95% CI = [16.5, 20.9]) and young adults (OR = 15.5, 95% CI = [14.7, 16.3]).

Figure 2 shows the proportions and ORs for receiving each type of psychotropic medications in individuals receiving ADHD medication prescriptions versus controls. Overall, individuals with ADHD medication prescriptions were more likely to take all types of psychotropic medications than population controls. In young adults, medications used in addictive disorders had the highest OR of being dispensed (OR = 26.6, 95% CI = [18.2, 38.8]), whereas in middle-aged adults and older adults, comedication with antipsychotics was the highest, with ORs of 26.3 (95% CI = [22.7, 30.3]) and 17.3 (95% CI = [13.6, 22.1]), respectively. The results remained consistent in individuals with both ADHD diagnosis and ADHD medication (Supplemental Figure S3). Supplemental Tables S6 to S11 list the most commonly dispensed medications in each type of psychotropic medications among individuals receiving ADHD medications.

Figure 2.

Dispensation of common psychotropic medications among individuals receiving ADHD medications, by age group.

Polypharmacy With ADHD Medications

Compared with population controls, individuals receiving ADHD medications had higher degree of polypharmacy from young adulthood to older age. They received on average 2.5 classes of other medications at age 18 to 5.0 classes at age 64, with the corresponding figures of 0.9 to 2.7 among population controls (Figure 3A). The proportion of polypharmacy with five or more medication classes increased from 10.1% at age 18 to 60.4% at age 64 among individuals receiving ADHD medications (Figure 3B).

Figure 3.

Comedication and polypharmacy among individuals receiving ADHD medications across age: (A) degree of polypharmacy, (B) number of comedicated drug classes.

Discussion

This Swedish nationwide study provides a comprehensive overview of comedication and polypharmacy patterns associated with ADHD medication in adults. Comedication with somatic medications was more common in adults who received ADHD medications compared with the general population, in particular with respiratory medications, alimentary tract and metabolic system medications, and cardiovascular system medications. Comedication with psychotropic medications was also common. Individuals receiving ADHD medications presented high degree of polypharmacy across age.

We found that the most commonly comedicated respiratory medications among individuals receiving ADHD medications were alimemazine, mometasone, and terbutaline (Supplemental Table S3). These medications are mainly used for allergic reactions and asthma. The increased odds of receiving respiratory medications is in line with findings that ADHD is associated with chronic conditions, such as eczema (Buske-Kirschbaum et al., 2013), asthma (Cortese et al., 2018), and allergic rhinitis (Schmitt et al., 2016), and smoking behavior (Modesto-Lowe et al., 2010). Another possible explanation for the coprescription pattern is that some antihistamines (alimemazine, promethazine [which is actually a low-potency antipsychotic], and hydroxyzine) might be prescribed to alleviate anxiety disorders, sleep disorders, nausea and vomiting, and as unspecific sedative medicine.

The most commonly dispensed alimentary tract and metabolic system medications across all age groups included proton pump inhibitors omeprazole and esomeprazole (Supplemental Table S4). These medications are indicated for gastric/duodenal ulcers and gastroesophageal reflux disease (GERD). However, no studies to date have evaluated the potential link between ADHD and gastric/duodenal ulcers or GERD. It is possible that proton pump inhibitors could shorten the time to maximum plasma concentration of ADHD medications, though the evidence is scarce and there are variations between different types of ADHD medications (Haffey et al., 2009). Another possible explanation is that proton pump inhibitors may have beneficial effects on sleep problems, though there is conflicting evidence for this (Rassameehiran et al., 2016). Our study also found increased odds of coprescription of sodium fluoride and its combinations, which are both indicated for dental caries. There is little evidence on dental caries among ADHD in the existing literature, with only a few small sample size studies conducted with inconsistent findings (Manoharan & Krishnamoorthy, 2016). The association between ADHD and dental diseases warrants further investigation. In addition, insulin preparations and metformin had high odds of coprescription, which is in line with studies showing that ADHD is associated with both obesity and diabetes (Instanes et al., 2018; Nigg, 2013). Although there is research suggesting that methylphenidate is associated with reducing energy intake in obese patients (Leddy et al., 2004), there are no clinical practice guidelines in Sweden supporting the use of ADHD medications in the treatment of obesity.

Regarding cardiovascular system medications, the most commonly dispensed ones—propranolol, metoprolol, and enalapril—are indicated for hypertension and arrhythmias (Supplemental Table S5). This might be explained by cardiovascular events or symptoms associated with ADHD (Fuemmeler et al., 2011), although there is a lack of consistent evidence. A review has found that ADHD is not associated with cardiovascular diseases (Instanes et al., 2018), but this study was based on only a limited number of studies with subjective measurements. Another possible explanation is that the use of ADHD medications might be associated with cardiovascular symptoms (e.g., heart rate and blood pressure elevations; Mick et al., 2013). The largest study evaluating the effect of ADHD medications on serious cardiovascular events in adults showed no significant association (Habel et al., 2011), whereas another study found the opposite (Schelleman et al., 2012). Further studies are needed to ascertain the underlying mechanism of the observed association between ADHD medications and cardiovascular medications. Apart from that, although the ORs of cardiovascular system medication use attenuated in older adults, the absolute difference was substantial (45% in ADHD medication group vs. 27.7% in control group), suggesting that comedication of cardiovascular medications and ADHD medications should not be overlooked in older adults.

The high proportion of psychotropic medications among individuals dispensed with ADHD medications presented in our study is consistent with previous studies in adolescents (Comer et al., 2010). The highest ORs with drugs for addictive disorders and antipsychotics are in line with the well-established link between ADHD and substance use disorder and schizophrenia–spectrum disorders (Larsson et al., 2013; Skoglund et al., 2015). Shared genetic and environmental factors may play a role in the comorbidities among major psychiatric disorders (Pettersson et al., 2016). In addition, the proportion of adults receiving opioids, specifically codeine combinations, tramadol, and oxycodone, was high (Supplemental Table S11). The high rate of opioids prescription is an important public health concern in the United States and many European countries (Bosetti et al., 2019; Curtis et al., 2019; Tuminello et al., 2019). Our findings suggest individuals with ADHD medications warrant further attention, considering their vulnerability to substance abuse.

Our results suggest that ADHD patients face serious multimorbidity and higher degree of polypharmacy from young ages, which would put challenges for the management of ADHD, as well as other comorbid conditions (Vanderwal, 2016). Future studies, including pharmacoepidemiological studies using real-world data (Chang et al., 2019), are needed to study comedication of specific drug–drug pairs (Johnell & Klarin, 2007), especially those with potential drug–drug interactions as reported in clinical databases such as DynaMed or Lexicomp.

The results of this study should be considered in light of its limitations. First, we used dispensed prescriptions from the PDR when assessing medication utilization, but cannot verify whether the dispensed medications were consumed. Second, we did not have information on the underlying indications for dispensations of medications, which means that we were unable to determine whether any of the ADHD or comorbid medications were dispensed for other problems or off-label use. However, there is no indication other than ADHD for which the use of ADHD medications is licensed in Sweden, though off-label use of ADHD medications to alleviate symptoms caused by narcolepsy and multiple sclerosis is possible but rare (Zetterqvist et al., 2013). In addition, in the sensitivity analysis where we have explored the associations among individuals with ADHD diagnosis and matched controls, we found consistent results with the main analysis. Third, individuals receiving ADHD medications may be more likely to be prescribed with other medications due to the more frequent visits and exposure to medical environment compared with controls. Fourth, our study includes most of the medications in the ATC classification system but not all ATC codes. Fifth, our results on comedication do not imply a causal relationship between ADHD medications and excess use of additional medications. Sixth, we used data on medication dispensations in 2013. Further replication with more recent data is warranted, especially after the introduction of the American Psychiatric Association’s (2013) Diagnostic and Statistical Manual of Mental Disorders (5th ed.; DSM-5), which relaxed the age limit of symptom onset from age 7 to 12 years in diagnosis of ADHD (Epstein & Loren, 2013). Finally, the clinical practices on prescribing medications vary between countries (NICE, 2018; Swedish: Socialstyrelsen, 2014; Wolraich et al., 2019). Thus, the comedication patterns derived from Sweden may not generalize to other contexts.

Clinical Implications

We found elevated rates of comedication and polypharmacy with somatic and psychotropic medications in adults receiving ADHD medications. Our findings provide new insights into the complex nature of comedication and polypharmacy with somatic medications among adults receiving ADHD medications, and call for future research to inform guideline development on optimal clinical practice.

Supplemental Material

Supplementary_material – Supplemental material for Comedication and Polypharmacy With ADHD Medications in Adults: A Swedish Nationwide Study

Supplemental material, Supplementary_material for Comedication and Polypharmacy With ADHD Medications in Adults: A Swedish Nationwide Study by Le Zhang, Andreas Reif, Ebba Du Rietz, Tyra Lagerberg, Agnieszka Butwicka, Brian M. D’Onofrio, Kristina Johnell, Nancy L. Pedersen, Henrik Larsson and Zheng Chang in Journal of Attention Disorders

Footnotes

Declaration of Conflicting Interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: AR has received speaker’s honoraria from Medice, Shire, Servier, Janssen, and Neuraxpharm, as well as grant support from Medice; HL has served as a speaker for Evolan Pharma and Shire and has received research grants from Shire; all outside the submitted work. The other authors declare no conflicts of interest.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study is supported by grants from the European Union’s Horizon 2020 research and innovation program: Comorbid Conditions of ADHD (CoCA; 667302); National Institute on Drug Abuse (R01DA048042); National Institute of Mental Health (R01MH102221); Swedish Research Council (2018-02599); Swedish Research Council for Health, Working Life, and Welfare (2019-01172); the Swedish Brain Foundation (FO2018-0273); and the Karolinska Institutet’s Research Foundation Grants. These funding agencies had no role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.

ORCID iDs

Le Zhang

Agnieszka Butwicka

Supplemental Material

Supplemental material for this article is available online.

Author Biographies

Le Zhang is a PhD student at the Department of Medical Epidemiology and Biostatistics, Karolinska Institute. Her research focuses on the developmental trajectory of ADHD into adulthood and aging.

Andreas Reif is a professor at the Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt, Goethe University. He is also a clinical psychiatrist with research interests in developmental psychiatry, especially ADHD and mood disorders.

Ebba Du Rietz is a postdoctoral researcher at the Depart-ment of Medical Epidemiology and Biostatistics, Karolinska Institute. Her research interests include genetic and developmental psychiatry.

Tyra Lagerberg is a PhD student at the Department of Medical Epidemiology and Biostatistics, Karolinska Institute. Her research focuses on unintended outcomes of antidepressants’ use.

Agnieszka Butwicka is a medical doctor, senior consultant in child and adolescent psychiatry with research interests in ADHD. She is also an assistant professor at the Department of Medical Epidemiology and Biostatistics, Karolinska Institute.

Brian M. D’Onofrio is a clinical psychological scientist who researches the causes and treatments of psychopathology in children and adolescents. He is a professor in the Department of Psychological and Brain Sciences at Indiana University, where he is also director of clinical training in the Clinical Science Program, and a visiting professor in the Department of Medical Epidemiology and Biostatistics, Karolinska Institute.

Kristina Johnell is a professor in geriatric pharmacoepidemiology and her research interests include personalized drug treatment, inappropriate drug use, and adverse drug events in elderly persons. She is the head of the Department of Medical Epidemiology and Biostatistics, Karolinska Institute.

Nancy L. Pedersen is a professor of genetic epidemiology. She has served as the vice chair and chair of the Department of Medical Epidemiology and Biostatistics, and as the vice dean of research at Karolinska Institute. Her research is based on the Swedish Twin Registry to study the genetic and environmental influences on characteristics and diseases.

Henrik Larsson is a professor of genetic epidemiology at the Department of Medical Epidemiology and Biostatistics, Karolinska Institute, and School of Medical Sciences, Örebro University. His main research interest is the influences of genes and environments on ADHD across the life span.

Zheng Chang is an assistant professor at the Department of Medical Epidemiology and Biostatistics, Karolinska Institute. His main interest research is psychiatric epidemiology and pharmacoepidemiology using large-scale population data.

References

American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). https://doi.org/10.1176/appi.books.9780890425596

Arruda

M. A.

Guidetti

Galli

Albuquerque

R. C. A. P.

Bigal

M. E.

(2010). Migraine, tension-type headache, and attention-deficit/hyperactivity disorder in childhood: A population-based study. Postgraduate Medicine, 122(5), 18–26. https://doi.org/10.3810/pgm.2010.09.2197

Bosetti

Santucci

Radrezza

Erthal

Berterame

Corli

(2019). Trends in the consumption of opioids for the treatment of severe pain in Europe, 1990–2016. European Journal of Pain, 23(4), 697–707. https://doi.org/10.1002/ejp.1337

Buske-Kirschbaum

Schmitt

Plessow

Romanos

Weidinger

Roessner

(2013). Psychoendocrine and psychoneuroimmunological mechanisms in the comorbidity of atopic eczema and attention deficit/hyperactivity disorder. Psychoneuroendocrinology, 38(1), 12–23. https://doi.org/10.1016/j.psyneuen.2012.09.017

Chang

Ghirardi

Quinn

P. D.

Asherson

D’Onofrio

B. M.

Larsson

(2019). Risks and benefits of attention-deficit/hyperactivity disorder medication on behavioral and neuropsychiatric outcomes: A qualitative review of pharmacoepidemiology studies using linked prescription databases. Biological Psychiatry, 86(5), 335–343. https://doi.org/10.1016/j.biopsych.2019.04.009

Comer

J. S.

Olfson

Mojtabai

(2010). National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996-2007. Journal of the American Academy of Child & Adolescent Psychiatry, 49(10), 1001–1010. https://doi.org/10.1016/j.jaac.2010.07.007

Cortese

Sun

Zhang

Sharma

Chang

Kuja-Halkola

. . . Faraone

S. V.

(2018). Association between attention deficit hyperactivity disorder and asthma: A systematic review and meta-analysis and a Swedish population-based study. Lancet Psychiatry, 5(9), 717–726. https://doi.org/10.1016/s2215-0366(18)30224-4

Curtis

H. J.

Croker

Walker

A. J.

Richards

G. C.

Quinlan

Goldacre

(2019). Opioid prescribing trends and geographical variation in England, 1998-2018: A retrospective database study. Lancet Psychiatry, 6(2), 140–150. https://doi.org/10.1016/s2215-0366(18)30471-1

Epstein

J. N.

Loren

R. E.

(2013). Changes in the definition of ADHD in DSM-5: Subtle but important. Neuropsychiatry, 3(5), 455–458.

10.

Faraone

S. V.

Biederman

Mick

(2006). The age-dependent decline of attention deficit hyperactivity disorder: A meta-analysis of follow-up studies. Psychological Medicine, 36(2), 159–165.

11.

Fluegge

(2018). Antecedent ADHD, dementia, and metabolic dysregulation: A U.S. based cohort analysis. Neurochemistry International, 112, 255–258. https://doi.org/10.1016/j.neuint.2017.08.005

12.

Fuemmeler

B. F.

Østbye

Yang

McClernon

F. J.

Kollins

S. H.

(2011). Association between attention-deficit/hyperactivity disorder symptoms and obesity and hypertension in early adulthood: A population-based study. International Journal of Obesity, 35(6), 852–862.

13.

Furu

Wettermark

Andersen

Martikainen

J. E.

Almarsdottir

A. B.

Sørensen

H. T.

(2010). The Nordic countries as a cohort for pharmacoepidemiological research. Basic & Clinical Pharmacology & Toxicology, 106(2), 86–94.

14.

Habel

L. A.

Cooper

W. O.

Sox

C. M.

Chan

K. A.

Fireman

B. H.

Arbogast

P. G.

. . . Selby

J. V.

(2011). ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. Journal of the American Medical Association, 306(24), 2673–2683. https://doi.org/10.1001/jama.2011.1830

15.

Haffey

M. B.

Buckwalter

Zhang

Homolka

Martin

Lasseter

K. C.

Ermer

J. C.

(2009). Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. Postgraduate Medicine, 121(5), 11–19. https://doi.org/10.3810/pgm.2009.09.2048

16.

Ingram

Hechtman

Morgenstern

(1999). Outcome issues in ADHD: Adolescent and adult long-term outcome. Mental Retardation and Developmental Disabilities Research Reviews, 5(3), 243–250.

17.

Instanes

J. T.

Klungsoyr

Halmoy

Fasmer

O. B.

Haavik

(2018). Adult ADHD and comorbid somatic disease: A systematic literature review. Journal of Attention Disorders, 22(3), 203–228. https://doi.org/10.1177/1087054716669589

18.

Johnell

Klarin

(2007). The relationship between number of drugs and potential drug-drug interactions in the elderly. Drug Safety, 30(10), 911–918. https://doi.org/10.2165/00002018-200730100-00009

19.

Karlstad

Zoega

Furu

Bahmanyar

Martikainen

J. E.

Kieler

Pottegard

(2016). Use of drugs for ADHD among adults-a multinational study among 15.8 million adults in the Nordic countries. European Journal of Clinical Pharmacology, 72(12), 1507–1514. https://doi.org/10.1007/s00228-016-2125-y

20.

Lagerberg

Molero

D’Onofrio

B. M.

Fernández de la Cruz

Lichtenstein

Mataix-Cols

. . . Chang

(2019). Antidepressant prescription patterns and CNS polypharmacy with antidepressants among children, adolescents, and young adults: A population-based study in Sweden. European Child & Adolescent Psychiatry, 28(8), 1137–1145. https://doi.org/10.1007/s00787-018-01269-2

21.

Larson

Russ

S. A.

Kahn

R. S.

Halfon

(2011). Patterns of comorbidity, functioning, and service use for US children with ADHD, 2007. Pediatrics, 127(3), 462–470.

22.

Larsson

Ryden

Boman

Langstrom

Lichtenstein

Landen

(2013). Risk of bipolar disorder and schizophrenia in relatives of people with attention-deficit hyperactivity disorder. British Journal of Psychiatry, 203(2), 103–106. https://doi.org/10.1192/bjp.bp.112.120808

23.

Leddy

J. J.

Epstein

L. H.

Jaroni

J. L.

Roemmich

J. N.

Paluch

R. A.

Goldfield

G. S.

Lerman

(2004). Influence of methylphenidate on eating in obese men. Obesity Research, 12(2), 224–232.

24.

Lichtenstein

Halldner

Zetterqvist

Sjölander

Serlachius

Fazel

. . . Larsson

(2012). Medication for attention deficit-hyperactivity disorder and criminality. New England Journal of Medicine, 367(21), 2006–2014. https://doi.org/10.1056/NEJMoa1203241

25.

Ludvigsson

J. F.

Almqvist

Bonamy

A.-K. E.

Ljung

Michaëlsson

Neovius

. . . Ye

(2016). Registers of the Swedish total population and their use in medical research. European Journal of Epidemiology, 31(2), 125–136.

26.

Ludvigsson

J. F.

Andersson

Ekbom

Feychting

Kim

J.-L.

Reuterwall

. . . Olausson

P. O.

(2011). External review and validation of the Swedish national inpatient register. BMC Public Health, 11(1), Article 450.

27.

Ludvigsson

J. F.

Otterblad-Olausson

Pettersson

B. U.

Ekbom

(2009). The Swedish personal identity number: Possibilities and pitfalls in healthcare and medical research. European Journal of Epidemiology, 24(11), 659–667.

28.

Manoharan

Krishnamoorthy

(2016). Dental caries and children with attention deficit hyperactivity disorder (ADHD)—A review. Journal of Pharmaceutical Sciences and Research, 8(7), 613–615.

29.

Mick

McManus

D. D.

Goldberg

R. J.

(2013). Meta-analysis of increased heart rate and blood pressure associated with CNS stimulant treatment of ADHD in adults. European Neuropsychopharmacology, 23(6), 534–541.

30.

Modesto-Lowe

Danforth

J. S.

Neering

Easton

(2010). Can we prevent smoking in children with ADHD: A review of the literature. Connecticut Medicine, 74(4), 229–236. http://europepmc.org/abstract/MED/20441004

31.

National Institute for Health and Care Excellence. (2018). Attention deficit hyperactivity disorder: Diagnosis and management. https://www.nice.org.uk/guidance/ng87

32.

Nigg

J. T.

(2013). Attention-deficit/hyperactivity disorder and adverse health outcomes. Clinical Psychology Review, 33(2), 215–228. https://doi.org/10.1016/j.cpr.2012.11.005

33.

Pearce

(2016). Analysis of matched case-control studies. British Medical Journal, 352, Article i969.

34.

Pettersson

Larsson

Lichtenstein

(2016). Common psychiatric disorders share the same genetic origin: A multivariate sibling study of the Swedish population. Molecular Psychiatry, 21(5), 717–721. https://doi.org/10.1038/mp.2015.116

35.

Polanczyk

G. V.

Willcutt

E. G.

Salum

G. A.

Kieling

Rohde

L. A.

(2014). ADHD prevalence estimates across three decades: An updated systematic review and meta-regression analysis. International Journal of Epidemiology, 43(2), 434–442. https://doi.org/10.1093/ije/dyt261

36.

Raman

S. R.

Man

K. K.

Bahmanyar

Berard

Bilder

Boukhris

. . . KaoYang

Y.-H.

(2018). Trends in attention-deficit hyperactivity disorder medication use: A retrospective observational study using population-based databases. The Lancet Psychiatry, 5(10), 824–835.

37.

Rassameehiran

Klomjit

Hosiriluck

Nugent

(2016). Meta-analysis of the effect of proton pump inhibitors on obstructive sleep apnea symptoms and indices in patients with gastroesophageal reflux disease. Proceedings (Baylor University Medical Center), 29(1), 3–6.

38.

Sarkar

(2017). Psychiatric polypharmacy, etiology and potential consequences. Current Psychopharmacology, 6(1), 12–26.

39.

Schelleman

Bilker

W. B.

Kimmel

S. E.

Daniel

G. W.

Newcomb

Guevara

J. P.

. . . Hennessy

(2012). Methylphenidate and risk of serious cardiovascular events in adults. American Journal of Psychiatry, 169(2), 178–185.

40.

Schmitt

Stadler

Kuster

Wustenberg

E. G.

(2016). Medical care and treatment of allergic rhinitis: A population-based cohort study based on routine healthcare utilization data. Allergy, 71(6), 850–858. https://doi.org/10.1111/all.12838

41.

Simon

Czobor

Balint

Meszaros

Bitter

(2009). Prevalence and correlates of adult attention-deficit hyperactivity disorder: Meta-analysis. British Journal of Psychiatry, 194(3), 204–211. https://doi.org/10.1192/bjp.bp.107.048827

42.

Sirois

Tannenbaum

Gagnon

M.-E.

Milhomme

Émond

(2016). Monitoring polypharmacy at the population level entails complex decisions: Results of a survey of experts in geriatrics and pharmacotherapy. Drugs & Therapy Perspectives, 32(6), 257–264.

43.

Skoglund

Chen

Franck

Lichtenstein

Larsson

(2015). Attention-deficit/hyperactivity disorder and risk for substance use disorders in relatives. Biological Psychiatry, 77(10), 880–886.

44.

Swedish National Board of Health and Welfare. (2014). Drug treatment of ADHD in children and adults: Support for treatment decisions. Socialstyrelsen. https://www.socialstyrelsen.se/globalassets/sharepoint-dokument/artikelkatalog/ovrigt/2015-4-14.pdf

45.

Thomas

Sanders

Doust

Beller

Glasziou

(2015). Prevalence of attention-deficit/hyperactivity disorder: A systematic review and meta-analysis. Pediatrics, 135(4), e994–e1001. https://doi.org/10.1542/peds.2014-3482

46.

Tuminello

Alpert

Flores

Taioli

(2019). Physician prescribing practices and opioid misuse in the USA. Lancet Psychiatry, 6(3), Article e7. https://doi.org/10.1016/s2215-0366(19)30029-x

47.

Vanderwal

(2016). Polypharmacy in attention-deficit/hyperactivity disorder: More than the sum of its parts? Journal of the American Academy of Child & Adolescent Psychiatry, 55(8), 641–642. http://www.sciencedirect.com/science/article/pii/S0890856716301800

48.

Wettermark

Hammar

Fored

C. M.

Leimanis

Otterblad Olausson

Bergman

. . . Rosen

(2007). The new Swedish Prescribed Drug Register—Opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiology and Drug Safety, 16(7), 726–735. https://doi.org/10.1002/pds.1294

49.

Wolraich

M. L.

Hagan

J. F.

Jr. Allan

Chan

Davison

Earls

. . . Zurhellen

(2019). Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics, 144(4), Article e20192528. https://doi.org/10.1542/peds.2019-2528

50.

Zetterqvist

Asherson

Halldner

Långström

Larsson

(2013). Stimulant and non-stimulant attention deficit/hyperactivity disorder drug use: Total population study of trends and discontinuation patterns 2006–2009. Acta Psychiatrica Scandinavica, 128(1), 70–77. https://doi.org/10.1111/acps.12004

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

1.32 MB